Medical devices, healthcare technology and the business of care
510(k) clearance · K260020

Redermo Wound Matrix

Beijing Kreate Medical Co., Ltd. · Decision date Apr 16, 2026

FDA DECISIONK260020

What did the FDA decide?

FDA records K260020 as a 510(k) premarket notification, with a decision dated Apr 16, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Unknown
Decision date
Apr 16, 2026

FDA source record

Regulatory record facts

Identifier
K260020
Regulatory pathway
510(k) premarket notification
Product code
QSZ
Decision code
SESE
Decision date
Apr 16, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Absorbable Synthetic Wound Dressing.

Product code
QSZ
FDA device class
U

FDA decision timeline

  1. K260020 received

    Application receipt date recorded by FDA.

  2. K260020 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code QSZ

Product / regulatory recordCompanyPathwayDecision dateSource
RestrataK261245
Acera Surgical, Inc.510(k) clearanceOct 16, 2026FDA
Anika Therapeutics, Inc.510(k) clearanceSep 2, 2026FDA
Huizhou Foryou Medical Devices Co., Ltd.510(k) clearanceAug 18, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Beijing Kreate Medical Co., Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Beijing

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records